
    
      This Phase 3b extension study will assess the long-term safety of Ace-ER in patients who
      participated in and completed study UX001-CL301 (NCT02377921), study UX001-CL202
      (NCT01830972), and study UX001-CL203 (NCT02731690).
    
  